{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T17:56:42Z","timestamp":1785779802257,"version":"3.56.0"},"reference-count":78,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:00:00Z","timestamp":1714348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Trastuzumab emtansine (T-DM1) has been approved worldwide for treating metastatic breast cancer (mBC) in patients who have received first-line therapy, shown disease progression, and are human epidermal growth factor receptor 2 (HER2)-positive. T-DM1 received approval in China to treat early-stage breast cancer (BC) in 2020 and for mBC in 2021. In March 2023, T-DM1 was included in medical insurance coverage, significantly expanding the eligible population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>This post-marketing observational study aimed to assess the safety and effectiveness of T-DM1 in real-world clinical practice in China. This study enrolled 31 individuals with HER2-positive early-stage BC and 70 individuals with HER2-positive advanced BC from 8 study centers in Shandong Province, China. The T-DM1 dosage was 3.6\u2009mg\/kg injected intravenously every 3\u2009weeks until the disease advanced or the drug toxicity became uncontrollable, whichever occurred earlier. Additionally, efficacy and safety information on T-DM1 were collected.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>During the 7-month follow-up period, no recurrence or metastases were observed in patients who had early-stage BC. The disease control rate was 31.43% (22\/70) in patients with advanced BC. The most common adverse effect of T-DM1 was thrombocytopenia, with an incidence of 69.31% (70\/101), and the probability of Grade\u2009\u2265\u20093 thrombocytopenia was 11.88% (12\/101).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This real-world study demonstrated that T-DM1 had good efficacy and was well tolerated by both HER2-positive early-stage BC and mBC patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2024.1383279","type":"journal-article","created":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T04:33:43Z","timestamp":1714365223000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of Trastuzumab Emtansine in treating human epidermal growth factor receptor 2-positive metastatic breast cancer in Chinese population: a real-world multicenter study"],"prefix":"10.3389","volume":"11","author":[{"given":"Miao","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanhan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zonghuai","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangye","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","article-title":"Breast Cancer","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nat Rev Dis Prim"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/cac2.12358","article-title":"Breast Cancer: An up-to-date review and future perspectives","volume":"42","author":"Hong","year":"2022","journal-title":"Cancer communications (London, England)"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast Cancer: correlation of relapse and survival with amplification of the her-2\/Neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science (New York, NY)"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1093\/annonc\/12.suppl_1.s3","article-title":"The basic biology of Her2","volume":"12","author":"Rubin","year":"2001","journal-title":"Annals of Oncol: Official J European Society for Medical Oncol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"4285","DOI":"10.1073\/pnas.89.10.4285","article-title":"Humanization of an anti-P185her2 antibody for human Cancer therapy","volume":"89","author":"Carter","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/s1535-6108(04)00083-2","article-title":"Insights into Erbb signaling from the structure of the Erbb2-Pertuzumab complex","volume":"5","author":"Franklin","year":"2004","journal-title":"Cancer Cell"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"6255","DOI":"10.1038\/sj.onc.1205794","article-title":"Anti-tumor activity of Gw572016: a dual tyrosine kinase inhibitor blocks Egf activation of Egfr\/Erbb2 and downstream Erk1\/2 and Akt pathways","volume":"21","author":"Xia","year":"2002","journal-title":"Oncogene"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/s1470-2045(15)00551-3","article-title":"Neratinib after Trastuzumab-based adjuvant therapy in patients with Her2-positive breast Cancer (Extenet): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"Chan","year":"2016","journal-title":"Lancet Oncol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, Trastuzumab, and docetaxel in Her2-positive metastatic breast Cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejca.2015.09.012","article-title":"Trastuzumab for Her2+ metastatic breast Cancer in clinical practice: cardiotoxicity and overall survival","volume":"52","author":"Rossi","year":"2016","journal-title":"European J Cancer (Oxford, England: 1990)"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40259-016-0162-9","article-title":"Trastuzumab in the treatment of breast Cancer","volume":"30","author":"Maximiano","year":"2016","journal-title":"BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"6469","DOI":"10.1038\/sj.onc.1210477","article-title":"The oncogene Her2: its signaling and transforming functions and its role in human Cancer pathogenesis","volume":"26","author":"Moasser","year":"2007","journal-title":"Oncogene"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3322\/caac.21634","article-title":"Evolving standards of care and new challenges in the management of Her2-positive breast Cancer","volume":"70","author":"Choong","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s10549-022-06575-7","article-title":"Clinical trial data and emerging strategies: Her2-positive breast Cancer","volume":"193","author":"Pernas","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting Her2-positive breast Cancer: advances and future directions","volume":"22","author":"Swain","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"9280","DOI":"10.1158\/0008-5472.Can-08-1776","article-title":"Targeting Her2-positive breast Cancer with Trastuzumab-Dm1, an antibody-cytotoxic drug conjugate","volume":"68","author":"Lewis Phillips","year":"2008","journal-title":"Cancer Res"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab Emtansine for Her2-positive advanced breast Cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"4436","DOI":"10.1158\/1078-0432.Ccr-14-0012","article-title":"Fda approval: ado-Trastuzumab Emtansine for the treatment of patients with Her2-positive metastatic breast Cancer","volume":"20","author":"Amiri-Kordestani","year":"2014","journal-title":"Clinical Cancer Res: Official J American Association for Cancer Res"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab Emtansine for residual invasive Her2-positive breast Cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid Tumours: revised Recist guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"European J Cancer (Oxford, England: 1990)"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1158\/2159-8290.Cd-20-1557","article-title":"Impact of Her2 heterogeneity on treatment response of early-stage Her2-positive breast Cancer: phase ii neoadjuvant clinical trial of T-Dm1 combined with Pertuzumab","volume":"11","author":"Filho","year":"2021","journal-title":"Cancer Discov"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/s1470-2045(17)30312-1","article-title":"Trastuzumab Emtansine versus Capecitabine plus Lapatinib in patients with previously treated Her2-positive advanced breast Cancer (Emilia): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial","volume":"18","author":"Di\u00e9ras","year":"2017","journal-title":"Lancet Oncol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus Capecitabine for Her2-positive advanced breast Cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1016\/j.ejca.2011.06.021","article-title":"Trastuzumab beyond progression: overall survival analysis of the Gbg 26\/big 3-05 phase iii study in Her2-positive breast Cancer","volume":"47","author":"von Minckwitz","year":"2011","journal-title":"European J Cancer (Oxford, England: 1990)"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/s1470-2045(17)30717-9","article-title":"Neratinib after Trastuzumab-based adjuvant therapy in Her2-positive breast Cancer (Extenet): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"18","author":"Martin","year":"2017","journal-title":"Lancet Oncol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.3816\/cbc.2008.s.005","article-title":"Treatment of metastatic Erbb2-positive breast Cancer: options after progression on Trastuzumab","volume":"8","author":"Spector","year":"2008","journal-title":"Clin Breast Cancer"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s11523-014-0350-9","article-title":"Prolonged complete remission of metastatic Her2-positive breast Cancer after continuous Trastuzumab treatment: a case report and review of the literature","volume":"10","author":"Ihnenfeld Arci\u00e9nega","year":"2015","journal-title":"Target Oncol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13058-021-01459-y","article-title":"Implementing antibody-drug conjugates (Adcs) in Her2-positive breast Cancer: state of the art and future directions","volume":"23","author":"Ferraro","year":"2021","journal-title":"Breast Cancer Res: BCR"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.3390\/ijms20051115","article-title":"Her2 directed antibody-drug-conjugates beyond T-Dm1 in breast Cancer","volume":"20","author":"Rinnerthaler","year":"2019","journal-title":"Int J Mol Sci"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.3390\/genes13112065","article-title":"Antibody-drug conjugates for the treatment of Her2-positive breast Cancer","volume":"13","author":"Najjar","year":"2022","journal-title":"Gen Dent"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41416-019-0635-y","article-title":"Mechanisms of resistance to Trastuzumab Emtansine (T-Dm1) in Her2-positive breast Cancer","volume":"122","author":"Hunter","year":"2020","journal-title":"Br J Cancer"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1038\/s41467-021-23793-7","article-title":"Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance","volume":"12","author":"Yamazaki","year":"2021","journal-title":"Nat Commun"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/s1470-2045(14)70178-0","article-title":"Trastuzumab Emtansine versus treatment of Physician's choice for pretreated Her2-positive advanced breast Cancer (Th3resa): a randomised, open-label, phase 3 trial","volume":"15","author":"Krop","year":"2014","journal-title":"Lancet Oncol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/s1470-2045(17)30313-3","article-title":"Trastuzumab Emtansine versus treatment of Physician's choice in patients with previously treated Her2-positive metastatic breast Cancer (Th3resa): final overall survival results from a randomised open-label phase 3 trial","volume":"18","author":"Krop","year":"2017","journal-title":"Lancet Oncol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1200\/jco.2012.44.9694","article-title":"Phase ii randomized study of Trastuzumab Emtansine versus Trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast Cancer","volume":"31","author":"Hurvitz","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2021.04.011","article-title":"Adjuvant T-Dm1 versus Trastuzumab in patients with residual invasive disease after neoadjuvant therapy for Her2-positive breast Cancer: subgroup analyses from Katherine","volume":"32","author":"Mamounas","year":"2021","journal-title":"Annals of Oncol: official J European Society for Medical Oncol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13058-022-01587-z","article-title":"Tumor biomarkers and efficacy in patients treated with Trastuzumab Emtansine\u2009+\u2009Pertuzumab versus standard of care in Her2-positive early breast Cancer: An open-label, phase iii study (Kristine)","volume":"25","author":"de Haas","year":"2023","journal-title":"Breast Cancer Res: BCR"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1200\/jco.19.00882","article-title":"Neoadjuvant Trastuzumab Emtansine and Pertuzumab in human epidermal growth factor receptor 2-positive breast Cancer: three-year outcomes from the phase iii Kristine study","volume":"37","author":"Hurvitz","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"3796","DOI":"10.1200\/jco.22.01816","article-title":"De-escalated neoadjuvant Trastuzumab-Emtansine with or without endocrine therapy versus Trastuzumab with endocrine therapy in Hr+\/Her2+ early breast Cancer: 5-year survival in the Wsg-Adapt-Tp trial","volume":"41","author":"Harbeck","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1200\/jco.2016.67.4887","article-title":"Trastuzumab Emtansine with or without Pertuzumab versus Trastuzumab plus Taxane for human epidermal growth factor receptor 2-positive, advanced breast Cancer: primary results from the phase iii Marianne study","volume":"35","author":"Perez","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1158\/1078-0432.Ccr-22-0855","article-title":"Phase I study and cell-free DNA analysis of T-Dm1 and metronomic Temozolomide for secondary prevention of Her2-positive breast Cancer Brain metastases","volume":"29","author":"Jenkins","year":"2023","journal-title":"Clinical Cancer Res: Official JAmerican Association for Cancer Res"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jamaoncol.2021.1932","article-title":"Neoadjuvant Trastuzumab, Pertuzumab, and docetaxel vs Trastuzumab Emtansine in patients with Erbb2-positive breast Cancer: a phase 2 randomized clinical trial","volume":"7","author":"Hatschek","year":"2021","journal-title":"JAMA Oncol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"100561","DOI":"10.1016\/j.esmoop.2022.100561","article-title":"Final results of the global and Asia cohorts of Kamilla, a phase Iiib safety trial of Trastuzumab Emtansine in patients with Her2-positive advanced breast Cancer","volume":"7","author":"Wuerstlein","year":"2022","journal-title":"ESMO open"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"e005119","DOI":"10.1136\/jitc-2022-005119","article-title":"Phase Ib study of Pembrolizumab in combination with Trastuzumab Emtansine for metastatic Her2-positive breast Cancer","volume":"10","author":"Waks","year":"2022","journal-title":"J Immunother Cancer"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ijrobp.2021.12.173","article-title":"Local therapy outcomes and toxicity from the Atempt trial (Tbcrc 033): a phase ii randomized trial of adjuvant Trastuzumab Emtansine versus paclitaxel in combination with Trastuzumab in women with stage I Her2-positive breast Cancer","volume":"113","author":"Bellon","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1001\/jamaoncol.2020.1796","article-title":"Efficacy and safety of Trastuzumab Emtansine plus Capecitabine vs Trastuzumab Emtansine alone in patients with previously treated Erbb2 (Her2)-positive metastatic breast Cancer: a phase 1 and randomized phase 2 trial","volume":"6","author":"Cort\u00e9s","year":"2020","journal-title":"JAMA Oncol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1200\/jco.21.00896","article-title":"Trastuzumab Emtansine plus Pertuzumab versus Taxane plus Trastuzumab plus Pertuzumab after anthracycline for high-risk human epidermal growth factor receptor 2-positive early breast Cancer: the phase iii Kaitlin study","volume":"40","author":"Krop","year":"2022","journal-title":"J Clin Oncol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1200\/jco.2011.40.5902","article-title":"A phase ii study of Trastuzumab Emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast Cancer who were previously treated with Trastuzumab, Lapatinib, an anthracycline, a Taxane, and Capecitabine","volume":"30","author":"Krop","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1093\/annonc\/mdw157","article-title":"Trastuzumab Emtansine (T-Dm1) plus docetaxel with or without Pertuzumab in patients with Her2-positive locally advanced or metastatic breast Cancer: results from a phase Ib\/Iia study","volume":"27","author":"Martin","year":"2016","journal-title":"Annals of Oncol: Official J European Society for Medical Oncol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1200\/jco.2013.52.6590","article-title":"Phase Iia trial of Trastuzumab Emtansine with Pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast Cancer","volume":"32","author":"Miller","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1200\/jco.2010.29.5865","article-title":"Phase ii study of the antibody drug conjugate Trastuzumab-Dm1 for the treatment of human epidermal growth factor receptor 2 (Her2)-positive breast Cancer after prior Her2-directed therapy","volume":"29","author":"Burris","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/j.annonc.2020.06.020","article-title":"Trastuzumab Emtansine (T-Dm1) in patients with Her2-positive metastatic breast Cancer and Brain metastases: exploratory final analysis of cohort 1 from Kamilla, a single-arm phase Iiib clinical trial(\u2606)","volume":"31","author":"Montemurro","year":"2020","journal-title":"Annals of Oncol: Official J European Society for Medical Oncol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1200\/jco.2009.26.2071","article-title":"Phase I study of Trastuzumab-Dm1, an Her2 antibody-drug conjugate, given every 3 weeks to patients with Her2-positive metastatic breast Cancer","volume":"28","author":"Krop","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/ppo.0000000000000144","article-title":"Trastuzumab Emtansine (T-Dm1) in patients with Her2-positive metastatic breast Cancer previously treated with chemotherapy and 2 or more Her2-targeted agents: results from the T-pas expanded access study","volume":"21","author":"Yardley","year":"2015","journal-title":"Cancer J (Sudbury, Mass)"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"110407","DOI":"10.1016\/j.biopha.2020.110407","article-title":"T-Dm1-induced thrombocytopenia in breast Cancer patients: new perspectives","volume":"129","author":"Liu","year":"2020","journal-title":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/09537104.2019.1637835","article-title":"How I approach new onset thrombocytopenia","volume":"31","author":"Swain","year":"2020","journal-title":"Platelets"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1182\/blood-2012-04-420968","article-title":"High-content live-cell imaging assay used to establish mechanism of Trastuzumab Emtansine (T-Dm1)--mediated inhibition of platelet production","volume":"120","author":"Thon","year":"2012","journal-title":"Blood"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1158\/1078-0432.Ccr-14-2093","article-title":"Potential mechanisms for thrombocytopenia development with Trastuzumab Emtansine (T-Dm1)","volume":"21","author":"Uppal","year":"2015","journal-title":"Clinical Cancer Res: Official J American Association for Cancer Res"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1158\/1535-7163.Mct-16-0710","article-title":"Inhibition of megakaryocyte differentiation by antibody-drug conjugates (Adcs) is mediated by macropinocytosis: implications for Adc-induced thrombocytopenia","volume":"16","author":"Zhao","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"e2200237","DOI":"10.1200\/po.22.00237","article-title":"Effect of ado-Trastuzumab Emtansine on autologous platelet kinetics and function","volume":"6","author":"Ansary","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"716","DOI":"10.3109\/07388551.2015.1015957","article-title":"Molecular mechanisms of drug resistance and its reversal in Cancer","volume":"36","author":"Kartal-Yandim","year":"2016","journal-title":"Crit Rev Biotechnol"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.bbcan.2016.10.001","article-title":"Novel mechanisms and approaches to overcome multidrug resistance in the treatment of ovarian Cancer","volume":"1866","author":"Ren","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1146\/annurev.med.53.082901.103929","article-title":"Mechanisms of Cancer drug resistance","volume":"53","author":"Gottesman","year":"2002","journal-title":"Annu Rev Med"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1016\/j.bmc.2016.04.055","article-title":"The 5-aromatic Hydantoin-3-acetate derivatives as inhibitors of the tumour multidrug resistance efflux pump P-glycoprotein (Abcb1): synthesis, crystallographic and biological studies","volume":"24","author":"\u017bes\u0142awska","year":"2016","journal-title":"Bioorg Med Chem"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"R182","DOI":"10.1007\/s004240100017","article-title":"The role of P-glycoprotein (Mdr1) polymorphisms and mutations in colorectal Cancer","volume":"442","author":"Potocnik","year":"2001","journal-title":"Pflugers Arch - Eur J Physiol"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/s0379-4172(06)60027-9","article-title":"Mdr1 gene polymorphisms and clinical relevance","volume":"33","author":"Li","year":"2006","journal-title":"Yi chuan xue bao = Acta genetica Sinica"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.cancergencyto.2008.01.023","article-title":"Common germline Mdr1\/Abcb1 functional polymorphisms and haplotypes modify susceptibility to colorectal cancers with high microsatellite instability","volume":"183","author":"Potocnik","year":"2008","journal-title":"Cancer Genet Cytogenet"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrc2167","article-title":"The resurgence of platinum-based Cancer chemotherapy","volume":"7","author":"Kelland","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2217\/14622416.9.1.105","article-title":"Abc multidrug transporters: structure, function and role in Chemoresistance","volume":"9","author":"Sharom","year":"2008","journal-title":"Pharmacogenomics"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.taap.2016.03.008","article-title":"In vitro and in vivo evaluations of the P-glycoprotein-mediated efflux of Dibenzoylhydrazines","volume":"298","author":"Miyata","year":"2016","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref71","first-page":"1137","article-title":"Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (Mdr)-1 gene","volume":"297","author":"Tanabe","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"ref72","first-page":"1086","article-title":"Frequency and clinical significance of the expression of the multidrug resistance proteins Mdr1\/P-glycoprotein, Mrp1, and Lrp in acute myeloid leukemia: a southwest oncology group study","volume":"94","author":"Leith","year":"1999","journal-title":"Blood"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1186\/s12885-017-3435-x","article-title":"Prognostic and predictive factors in patients with metastatic or recurrent cervical Cancer treated with platinum-based chemotherapy","volume":"17","author":"Karageorgopoulou","year":"2017","journal-title":"BMC Cancer"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1158\/1078-0432.Ccr-05-0950","article-title":"Mdr-1 single nucleotide polymorphisms in ovarian Cancer tissue: G2677t\/a correlates with response to paclitaxel chemotherapy","volume":"12","author":"Gr\u00e9en","year":"2006","journal-title":"Clinical Cancer Res: Official J American Association for Cancer Res"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/sj.bjc.6605587","article-title":"Influence of pharmacogenetics on response and toxicity in breast Cancer patients treated with doxorubicin and cyclophosphamide","volume":"102","author":"Bray","year":"2010","journal-title":"Br J Cancer"},{"key":"ref76","first-page":"265","article-title":"Abcb1 (Rs1128503) polymorphism and response to chemotherapy in patients with malignant tumors-evidences from a Meta-analysis","volume":"8","author":"Zhou","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"ref77","first-page":"5141","article-title":"Isolation of amplified and overexpressed DNA sequences from Adriamycin-resistant human breast Cancer cells","volume":"47","author":"Fairchild","year":"1987","journal-title":"Cancer Res"},{"key":"ref78","first-page":"655","article-title":"Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and Ifosfamide activation based on Cdna-expressed activities and liver microsomal P-450 profiles","volume":"27","author":"Roy","year":"1999","journal-title":"Drug Metab Dispos"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1383279\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T04:33:48Z","timestamp":1714365228000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1383279\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,29]]},"references-count":78,"alternative-id":["10.3389\/fmed.2024.1383279"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1383279","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,29]]},"article-number":"1383279"}}